Immuno-Oncology in China
Home



Clinical Trial Results

厄洛替尼作为 IIIA (N2) 期 EGFR 突变阳性非小细胞肺癌的新辅助治疗:前瞻性单组 II 期研究
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi, Hua Zhong, Aiqin Gu, Liyan Jiang, Jianxing Shi, Wentao Fang, Heng Zhao, Jie Zhang, Junyuan Wang, Junyi Ye, Baohui Han
The Oncologist 2019; 24:157-e64; first published on August 29, 2018; doi:10.1634/theoncologist.2018-0120

评估胃肠癌患者缩短注射雷莫芦单抗时间安全性的前瞻性试验
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
Naoya Hashimoto, Seiichiro Mitani, Hiroya Taniguchi, Yukiya Narita, Kyoko Kato, Toshiki Masuishi, Shigenori Kadowaki, Sachiyo Onishi, Masahiro Tajika, Shinji Takahashi, Kazuhiro Shimomura, Chihoko Takahata, Eri Hotta, Makiko Kobara, Kei Muro
The Oncologist 2019; 24:159-e66; first published on October 10, 2018; doi:10.1634/theoncologist.2018-0580

激活素受体样激酶 1 配体陷阱 Dalantercept 联合索拉非尼治疗晚期肝细胞癌的 Ib 期开放标签研究
A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, Rebecca A. Miksad, Mohamedtaki A. Tejani, Stephen Williamson, Martin E. Gutierrez, Olugbenga O. Olowokure, Manish R. Sharma, Imane El Dika, Matthew L. Sherman, Shuchi S. Pandya
The Oncologist 2019; 24:161-e70; first published on October 23, 2018; doi:10.1634/theoncologist.2018-0654

5-氟尿嘧啶、多西紫杉醇和奈达铂 (UDON) 联合治疗复发或转移性食管癌的 II 期试验
Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
Hiroto Ueda, Hisato Kawakami, Yoshikane Nonagase, Naoki Takegawa, Tatsuya Okuno, Takayuki Takahama, Masayuki Takeda, Yasutaka Chiba, Takao Tamura, Kazuhiko Nakagawa
The Oncologist 2019; 24:163-e76; first published on October 25, 2018; doi:10.1634/theoncologist.2018-0653


Breast Cancer

在雌激素受体阳性、HER-2 阴性乳腺癌患者中,根据亚型估计孕激素受体预后价值
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor‐Positive, HER‐2 Negative Breast Cancer
Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, Lynn Jongen, Olivier Brouckaert, Hans Wildiers, Giuseppe Floris, Erik Van Limbergen, Caroline Weltens, Ann Smeets, Robert Paridaens, Anita Giobbie‐Hurder, Meredith M. Regan, Giuseppe Viale, Beat Thürlimann, Ignace Vergote, Evangelia Christodoulou, Ben Van Calster, Patrick Neven
The Oncologist 2019; 24:165-171; first published on August 31, 2018; doi:10.1634/theoncologist.2018-0176

乳腺癌保乳治疗的美容影响:值得一谈的事
Cosmetic Consequences of Breast‐Conserving Treatment for Breast Cancer: Something Worth Talking About
Angelique Brands‐Appeldoorn, Sabrina Maaskant‐Braat, Karin Schenk, Rudi Roumen
The Oncologist 2019; 24:172-177; first published on September 26, 2018; doi:10.1634/theoncologist.2017-0443

长期服用唑来膦酸对骨饱和的间接评估
Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long‐Term Dosing
Gabriel N. Hortobagyi, Ming Zheng, Ramon Mohanlal
The Oncologist 2019; 24:178-184; first published on October 8, 2018; doi:10.1634/theoncologist.2018-0218


Gastrointestinal Cancer

经标准治疗后进展的转移性结直肠癌患者的瑞戈非尼的应用:大规模、单臂、开放标签 IIIb 期 CONSIGN 研究的结果
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study
Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, Jean‐François Seitz, Carlo Barone, Marc Ychou, Marc Peeters, Baruch Brenner, Ralf Dieter Hofheinz, Evaristo Maiello, Thierry André, Andrea Spallanzani, Rocio Garcia‐Carbonero, Yull E. Arriaga, Udit Verma, Axel Grothey, Christian Kappeler, Ashok Miriyala, Joachim Kalmus, Alfredo Falcone, Alberto Zaniboni
The Oncologist 2019; 24:185-192; first published on September 6, 2018; doi:10.1634/theoncologist.2018-0072

原发胃肠恶性肿瘤脑转移中 HER2 扩增的富集
Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies
Devarati Mitra, Jeffrey W. Clark, Helen A. Shih, Kevin S. Oh, Priscilla K. Brastianos, Jennifer Y. Wo, Matthew R. Strickland, William T. Curry, Aparna R. Parikh, Ryan B. Corcoran, David P. Ryan, A. John Iafrate, Darrell R. Borger, Jochen K. Lennerz, Theodore S. Hong
The Oncologist 2019; 24:193-201; first published on October 29, 2018; doi:10.1634/theoncologist.2018-0152


Lung Cancer

癌症患者的烟草使用情况评估及戒烟治疗:美国肿瘤学临床医师遵循临床实践指南的范围综述
Tobacco Use Assessment and Treatment in Cancer Patients: A Scoping Review of Oncology Care Clinician Adherence to Clinical Practice Guidelines in the U.S.
Sarah N. Price, Jamie L. Studts, Heidi A. Hamann
The Oncologist 2019; 24:229-238; first published on November 16, 2018; doi:10.1634/theoncologist.2018-0246


Symptom Management and Supportive Care

心血管自主神经功能临床指标与乳腺癌治疗和运动训练之间关联的纵向研究
A Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training
Amy A. Kirkham, Matthew G. Lloyd, Victoria E. Claydon, Karen A. Gelmon, Donald C. McKenzie, Kristin L. Campbell
The Oncologist 2019; 24:273-284; first published on September 26, 2018; doi:10.1634/theoncologist.2018-0049